Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder.
Findling RL, Kauffman R, Sallee FR, Salazar DE, Sahasrabudhe V, Kollia G, Kornhauser DM, Vachharajani NN, Assuncao-Talbott S, Mallikaarjun S, Iwamoto T, McQuade RD, Boulton DW, Blumer J. Findling RL, et al. Among authors: kornhauser dm. J Child Adolesc Psychopharmacol. 2009 Aug;19(4):431-9. doi: 10.1089/cap.2008.0111. J Child Adolesc Psychopharmacol. 2009. PMID: 19702495
Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers.
Pieniaszek HJ Jr, Sy SK, Ebling W, Fossler MJ, Cain VA, Mondick JT, Ma S, Kornhauser DM. Pieniaszek HJ Jr, et al. Among authors: kornhauser dm. J Clin Pharmacol. 2002 Jul;42(7):738-53. doi: 10.1177/009127002401102687. J Clin Pharmacol. 2002. PMID: 12092741 Clinical Trial.
42 results